Atezolizumab (Tecentriq) is a fully humanized，engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). Atezolizumab blocks the interaction of PD-L1 with PD-1 and induces anti-tumor immune reactivation.
